Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Immuneering Corporation on June 13, 2025. The filing details the voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A total of 24,866,430 shares were present or represented by proxy, representing approximately 69.1% of outstanding Class A common stock as of the April 17, 2025 record date. All proposals were approved:
- Item 1 (Director Elections): Ann E. Berman, Diana F. Hausman, M.D., and Thomas J. Schall, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Attendance at the Annual Meeting was 69.1% of outstanding shares.
- Three new Class I directors were elected with zero votes against any nominee.
- RSM US LLP was ratified as the independent auditor for the 2025 fiscal year.
- The report contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.